Shareholders request that the Board of Directors adopt an enduring policy, and amend the governing documents as necessary including the Corporate Governance Guidelines in order that 2 separate people hold the office of the Chairman and the office of the CEO as soon as possible. The Chairman of the Board shall be an Independent Director. A Lead Director shall not be a substitute for an independent Board Chairman. The Board shall have the discretion to select an interim Chairman of the Board, who is not an Independent Director, to serve while the Board is required to seek an Independent Chairman of the Board on an accelerated basis. This policy could be phased in when there is a contract renewal for our current CEO or for the next CEO transition although it is better to adopt it now. An independent Board Chairman at all times improves corporate governance by bringing impartiality, objective oversight, and external expertise to board decisions, mitigating conflicts of interest, enhancing transparency, and boosting shareholder confidence. This detached perspective allows the chairman to focus on shareholder interests, strengthen management accountability, and provide critical checks and balances, ultimately contributing to long term sustainability and credibility. Now could be a ripe time for this policy since Teleflex stock was at $449 in 2021 and was down drastically to only $119 in late 2025 despite a robust stock market. Plus challenging news reports regarding TFX emerged in 2025: • Teleflex’s stock fell 20% on February 27, 2025, following the announcement of a business split, the resignation of its CFO, and the acquisition of BIOTRONIK’s vascular intervention business. • The steep drop in the company’s stock, coupled with the business split and CFO resignation, led to multiple shareholder rights law firms announcing securities fraud investigations into Teleflex in early 2025 including Bleakman Fonti & Auld LLP and Levi & Korsinsky. • The company reported a 5% year over year decline in GAAP revenue during the first quarter of 2025. This was attributed to challenges in its OEM business, softness in its UroLift product line, and supply chain issues. • Due to tariffs and acquisition related expenses, Teleflex lowered its full year adjusted diluted earnings per share guidance in May 2025. • Throughout the year, Teleflex’s stock continued to underperform compared to competitors. • Analysts raised concerns regarding the company’s decision to split into two entities. A Seeking Alpha report questioned how separating underperforming segments would improve performance. • Multiple business segments, including the original equipment manufacturer and Interventional Urology businesses, showed weakness.